A Phase 3, open-label study evaluating the Long-term safety and efficacy of VX-121 combination therapy in subjects with Cystic Fibrosis (VX20-121-104)
The purpose of this study is to evaluate the long-term safety,
tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor
(VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
Study details
Study-ID: NCT05444257, 2024-514173-22-00
Study-ID: NCT05444257, 2024-514173-22-00
DZL Disease Area: CFBE
DZL Disease Area: CFBE
Study Type: Interventional
Study Type: Interventional
DZL Role: DZL recruiting center, DZL on steering board
DZL Role: DZL recruiting center, DZL on steering board
Funding: Externally - industry
Funding: Externally - industry
DZL Participating Sites: UGMLC, BIH / Charité - Associated Partner
DZL Participating Sites: UGMLC, BIH / Charité - Associated Partner
Unsere Seite verwendet Cookies und ähnliche Technologien. Mit der Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu.
Mehr Informationen dazu finden Sie in unserer Datenschutzerklärung.
